

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 June 2023 (22.06.2023)



(10) International Publication Number
WO 2023/114809 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) A61P 35/00 (2006.01)
C07D 471/04 (2006.01) A61K 31/4375 (2006.01)

(21) International Application Number:

PCT/US2022/081504

(22) International Filing Date:

14 December 2022 (14.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/290,291 16 December 2021 (16.12.2021) US
63/301,267 20 January 2022 (20.01.2022) US
63/380,049 18 October 2022 (18.10.2022) US
63/386,647 08 December 2022 (08.12.2022) US

(71) Applicant: **KINNATE BIOPHARMA INC.** [US/US];
12830 El Camino Real, Suite 150, San Diego, California
92130 (US).

(72) Inventors: **OUYANG, Xiaohu S.**; 12830 El Camino Real,
Suite 150, San Diego, California 92130 (US). **KANOUNI,
Toufik**; 12830 El Camino Real, Suite 150, San Diego,
California 92130 (US). **TYHONAS, John, S.**; 12830 El
Camino Real, Suite 150, San Diego, California 92130 (US).
COX, Jason, M.; 12830 El Camino Real, Suite 150, San
Diego, California 92130 (US). **KANIA, Robert**; 12830 El
Camino Real, Suite 150, San Diego, California 92130 (US).

(74) Agent: **CLARK, David**; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, California 94304
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF MET KINASE



(57) Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.

WO 2023/114809 A1